Evidence map›Paper›PMID 36389165›Full record

ArticleFrontiers in cellular and infection microbiology2022

A maximum-type microbial differential abundance test with application to high-dimensional microbiome data analyses.

Zhengbang Li, Xiaochen Yu, Hongping Guo, TingFang Lee, Jiyuan Hu

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhengbang LiSchool of Mathematics and Statistics, Central China Normal University, Wuhan, China.
Xiaochen YuSchool of Mathematics and Statistics, Central China Normal University, Wuhan, China.
Hongping GuoSchool of Mathematics and Statistics, Hubei Normal University, Huangshi, China.
TingFang LeeDivision of Biostatistics, Department of Population Health, New York University (NYU) Grossman School of Medicine, New York, NY, United States.
Jiyuan HuDivision of Biostatistics, Department of Population Health, New York University (NYU) Grossman School of Medicine, New York, NY, United States.

Funding

Scaling Community-Clinical Linkage Models to Address Diabetes and Hypertension Disparities in the Southeastern U.S.U54MD000538 · NIMHD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI TRINH-SHEVRIN, CHAU · 2017 to 2022
$11.3M
EHR nudges: Development and testing of a behavioral economics electronic health record moduleR33AG057382 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MANN, DEVIN M, TROXEL, ANDREA B · 2019 to 2021
$2.2M
NIA NIH HHS R33 AG057382NIMHD NIH HHS U54 MD000538
6 · The paper itself

Abstract

Background: High-throughput metagenomic sequencing technologies have shown prominent advantages over traditional pathogen detection methods, bringing great potential in clinical pathogen diagnosis and treatment of infectious diseases. Nevertheless, how to accurately detect the difference in microbiome profiles between treatment or disease conditions remains computationally challenging. Results: In this study, we propose a novel test for identifying the difference between two high-dimensional microbiome abundance data matrices based on the centered log-ratio transformation of the microbiome compositions. The test p-value can be calculated directly with a closed-form solution from the derived asymptotic null distribution. We also investigate the asymptotic statistical power against sparse alternatives that are typically encountered in microbiome studies. The proposed test is maximum-type equal-covariance-assumption-free (MECAF), making it widely applicable to studies that compare microbiome compositions between conditions. Our simulation studies demonstrated that the proposed MECAF test achieves more desirable power than competing methods while having the type I error rate well controlled under various scenarios. The usefulness of the proposed test is further illustrated with two real microbiome data analyses. The source code of the proposed method is freely available at https://github.com/Jiyuan-NYU-Langone/MECAF. Conclusions: MECAF is a flexible differential abundance test and achieves statistical efficiency in analyzing high-throughput microbiome data. The proposed new method will allow us to efficiently discover shifts in microbiome abundances between disease and treatment conditions, broadening our understanding of the disease and ultimately improving clinical diagnosis and treatment.

Indexed as

Data AnalysisMicrobiotaComputer SimulationHigh-Throughput Nucleotide Sequencingdifferential abundance analysishigh-dimensional compositionalmicrobiome datarelative abundancessparse alternatives

Identifiers

PMID36389165
PMCPMC9650337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.